Senior US District Judge Rebecca Beach Smith has granted approval for a $70 million settlement reached between a class of drug purchasers and pharmaceutical giants Merck and Glenmark Pharmaceuticals. This settlement arises from allegations of collusion between the two companies to delay the release of a generic version of Merck’s popular anti-cholesterol drug, Zetia, reported Reuters.
Judge Smith delivered her ruling on Wednesday, affirming that the settlement was “fair, reasonable, and adequate.” This decision allows the plaintiffs, which encompass various municipal employee benefit funds, to mitigate the risks associated with a protracted trial. The court’s approval effectively concludes a five-year antitrust litigation saga centered around Merck’s Zetia.
Read more: Merck, Glenmark Must Face Antitrust Trial Over Drug Pricing
Additionally, Judge Smith has endorsed a request made by the plaintiffs’ legal representatives, which include Motley Rice and Miller Law, for a total of $23.3 million in fees. This amount represents one-third of the overall settlement, coupled with $3.9 million in costs. The judge determined that this request was not excessive and aligned with precedents from comparable cases within the pharmaceutical industry.
As of now, there has been no immediate response from Merck, Glenmark, or the plaintiffs’ legal representatives regarding this development.
The initial complaint, filed by the plaintiffs in 2018, alleged that both Merck and Glenmark violated antitrust laws as a result of a 2010 settlement. This settlement saw Merck relinquishing its patent infringement claims against Glenmark’s proposed generic version of Zetia, with Glenmark agreeing to postpone the release of their generic product for nearly five years.
Source: Reuters
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI